CA1260397B - Traitement de l'acne et des dermatites periorales ainsi que des infections de la peau par le virus de l'herpes - Google Patents

Traitement de l'acne et des dermatites periorales ainsi que des infections de la peau par le virus de l'herpes

Info

Publication number: CA1260397B
Authority: CA; Canada
Prior art keywords: triacontanol; composition; carrier; treatment; hydrophilic ointment
Prior art date: 1989-03-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000594169A

Other languages

English (en)

Inventor

Lealand L. Clark

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-03-17

Filing date

1989-03-17

Publication date

1989-09-26

1989-03-17 Application filed by Individual filed Critical Individual

1989-03-17 Priority to CA000594169A priority Critical patent/CA1260397B/fr

1989-09-26 Application granted granted Critical

1989-09-26 Publication of CA1260397B publication Critical patent/CA1260397B/fr

Status Expired legal-status Critical Current

Links

238000011282 treatment Methods 0.000 title claims abstract description 87
201000004624 Dermatitis Diseases 0.000 title claims description 73
206010000496 acne Diseases 0.000 title claims description 50
208000002874 Acne Vulgaris Diseases 0.000 title claims description 47
241001529453 unidentified herpesvirus Species 0.000 title claims description 33
208000009675 Perioral Dermatitis Diseases 0.000 title claims description 31
REZQBEBOWJAQKS-UHFFFAOYSA-N triacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO REZQBEBOWJAQKS-UHFFFAOYSA-N 0.000 claims abstract description 169
208000009889 Herpes Simplex Diseases 0.000 claims abstract description 38
208000007514 Herpes zoster Diseases 0.000 claims abstract description 14
239000002674 ointment Substances 0.000 claims abstract description 13
206010012442 Dermatitis contact Diseases 0.000 claims abstract description 6
206010039793 Seborrhoeic dermatitis Diseases 0.000 claims abstract description 6
208000010247 contact dermatitis Diseases 0.000 claims abstract description 6
208000008742 seborrheic dermatitis Diseases 0.000 claims abstract description 6
201000004681 Psoriasis Diseases 0.000 claims abstract description 5
206010068172 Anal pruritus Diseases 0.000 claims abstract description 3
206010012468 Dermatitis herpetiformis Diseases 0.000 claims abstract description 3
201000009053 Neurodermatitis Diseases 0.000 claims abstract description 3
208000009544 Pruritus Ani Diseases 0.000 claims abstract description 3
206010048222 Xerosis Diseases 0.000 claims abstract description 3
208000001875 irritant dermatitis Diseases 0.000 claims abstract description 3
201000011486 lichen planus Diseases 0.000 claims abstract description 3
208000034189 Sclerosis Diseases 0.000 claims abstract 2
208000010668 atopic eczema Diseases 0.000 claims description 41
239000008311 hydrophilic ointment Substances 0.000 claims description 39
239000000203 mixture Substances 0.000 claims description 35
241000700605 Viruses Species 0.000 claims description 14
239000003937 drug carrier Substances 0.000 claims description 10
239000000126 substance Substances 0.000 claims description 8
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 5
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 5
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 5
239000005642 Oleic acid Substances 0.000 claims description 5
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 5
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 5
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 5
238000002360 preparation method Methods 0.000 abstract description 62
201000008937 atopic dermatitis Diseases 0.000 abstract description 20
206010012438 Dermatitis atopic Diseases 0.000 abstract description 17
230000000699 topical effect Effects 0.000 abstract description 12
239000003883 ointment base Substances 0.000 abstract description 2
208000027866 inflammatory disease Diseases 0.000 abstract 1
230000003902 lesion Effects 0.000 description 52
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 38
210000003491 skin Anatomy 0.000 description 36
208000035475 disorder Diseases 0.000 description 24
208000015181 infectious disease Diseases 0.000 description 17
230000000694 effects Effects 0.000 description 16
208000003251 Pruritus Diseases 0.000 description 15
235000013871 bee wax Nutrition 0.000 description 14
239000012166 beeswax Substances 0.000 description 14
201000010099 disease Diseases 0.000 description 14
230000035876 healing Effects 0.000 description 14
230000007803 itching Effects 0.000 description 13
238000000034 method Methods 0.000 description 12
208000002193 Pain Diseases 0.000 description 9
239000006071 cream Substances 0.000 description 9
230000004054 inflammatory process Effects 0.000 description 9
208000001688 Herpes Genitalis Diseases 0.000 description 8
208000004898 Herpes Labialis Diseases 0.000 description 8
206010061218 Inflammation Diseases 0.000 description 8
201000004946 genital herpes Diseases 0.000 description 8
208000024891 symptom Diseases 0.000 description 8
206010067152 Oral herpes Diseases 0.000 description 7
239000003862 glucocorticoid Substances 0.000 description 7
208000017520 skin disease Diseases 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
241000700584 Simplexvirus Species 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
230000003247 decreasing effect Effects 0.000 description 6
231100001078 no known side-effect Toxicity 0.000 description 6
206010073931 Genital herpes simplex Diseases 0.000 description 5
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 5
206010037660 Pyrexia Diseases 0.000 description 5
239000003242 anti bacterial agent Substances 0.000 description 5
229940088710 antibiotic agent Drugs 0.000 description 5
230000007794 irritation Effects 0.000 description 5
230000004044 response Effects 0.000 description 5
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 4
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 4
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 4
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
206010037888 Rash pustular Diseases 0.000 description 4
208000036142 Viral infection Diseases 0.000 description 4
230000002411 adverse Effects 0.000 description 4
230000003110 anti-inflammatory effect Effects 0.000 description 4
-1 cleansers Substances 0.000 description 4
229960004544 cortisone Drugs 0.000 description 4
229940088597 hormone Drugs 0.000 description 4
239000005556 hormone Substances 0.000 description 4
208000014674 injury Diseases 0.000 description 4
239000002085 irritant Substances 0.000 description 4
231100000021 irritant Toxicity 0.000 description 4
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
208000029561 pustule Diseases 0.000 description 4
230000001568 sexual effect Effects 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
230000009385 viral infection Effects 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
206010003645 Atopy Diseases 0.000 description 3
201000006082 Chickenpox Diseases 0.000 description 3
208000032544 Cicatrix Diseases 0.000 description 3
206010014198 Eczema infantile Diseases 0.000 description 3
206010033733 Papule Diseases 0.000 description 3
206010035148 Plague Diseases 0.000 description 3
206010035664 Pneumonia Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000004098 Tetracycline Substances 0.000 description 3
206010046980 Varicella Diseases 0.000 description 3
241000607479 Yersinia pestis Species 0.000 description 3
230000001605 fetal effect Effects 0.000 description 3
210000004392 genitalia Anatomy 0.000 description 3
208000006454 hepatitis Diseases 0.000 description 3
231100000283 hepatitis Toxicity 0.000 description 3
201000006747 infectious mononucleosis Diseases 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
230000008439 repair process Effects 0.000 description 3
231100000241 scar Toxicity 0.000 description 3
230000037387 scars Effects 0.000 description 3
230000035807 sensation Effects 0.000 description 3
239000000344 soap Substances 0.000 description 3
229960002180 tetracycline Drugs 0.000 description 3
229930101283 tetracycline Natural products 0.000 description 3
235000019364 tetracycline Nutrition 0.000 description 3
150000003522 tetracyclines Chemical class 0.000 description 3
230000008733 trauma Effects 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
208000037976 chronic inflammation Diseases 0.000 description 2
230000006020 chronic inflammation Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000000470 constituent Substances 0.000 description 2
239000002537 cosmetic Substances 0.000 description 2
208000031513 cyst Diseases 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
210000004207 dermis Anatomy 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
229960003276 erythromycin Drugs 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
210000001508 eye Anatomy 0.000 description 2
210000002683 foot Anatomy 0.000 description 2
230000012010 growth Effects 0.000 description 2
210000004247 hand Anatomy 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
230000005906 menstruation Effects 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
235000019271 petrolatum Nutrition 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
229930002330 retinoic acid Natural products 0.000 description 2
210000004761 scalp Anatomy 0.000 description 2
230000003068 static effect Effects 0.000 description 2
229940037128 systemic glucocorticoids Drugs 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
239000003871 white petrolatum Substances 0.000 description 2
CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
206010000349 Acanthosis Diseases 0.000 description 1
206010003226 Arteriovenous fistula Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
239000004342 Benzoyl peroxide Substances 0.000 description 1
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
101100162706 Caenorhabditis elegans ani-3 gene Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
208000032170 Congenital Abnormalities Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
241000709687 Coxsackievirus Species 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
208000035874 Excoriation Diseases 0.000 description 1
208000001860 Eye Infections Diseases 0.000 description 1
206010016275 Fear Diseases 0.000 description 1
206010019973 Herpes virus infection Diseases 0.000 description 1
208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
206010061217 Infestation Diseases 0.000 description 1
208000006877 Insect Bites and Stings Diseases 0.000 description 1
241000219823 Medicago Species 0.000 description 1
235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
206010042496 Sunburn Diseases 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
229930003268 Vitamin C Natural products 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
238000005299 abrasion Methods 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
210000003423 ankle Anatomy 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
239000003908 antipruritic agent Substances 0.000 description 1
229940064004 antiseptic throat preparations Drugs 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
235000019400 benzoyl peroxide Nutrition 0.000 description 1
229940064804 betadine Drugs 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000007698 birth defect Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
230000006931 brain damage Effects 0.000 description 1
231100000874 brain damage Toxicity 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
210000001217 buttock Anatomy 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960002227 clindamycin Drugs 0.000 description 1
KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000000315 cryotherapy Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
235000018927 edible plant Nutrition 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
208000011323 eye infectious disease Diseases 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
210000000887 face Anatomy 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
239000003337 fertilizer Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
208000020694 gallbladder disease Diseases 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000035992 intercellular communication Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000037323 metabolic rate Effects 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
210000000944 nerve tissue Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
229940127249 oral antibiotic Drugs 0.000 description 1
239000003973 paint Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
208000014232 psoriasis 12 Diseases 0.000 description 1
230000003236 psychic effect Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
230000037390 scarring Effects 0.000 description 1
230000001932 seasonal effect Effects 0.000 description 1
210000001732 sebaceous gland Anatomy 0.000 description 1
239000008306 shake lotion Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003351 stiffener Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
210000000707 wrist Anatomy 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Landscapes

Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA000594169A 1989-03-17 1989-03-17 Traitement de l'acne et des dermatites periorales ainsi que des infections de la peau par le virus de l'herpes Expired CA1260397B (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000594169A CA1260397B (fr)	1989-03-17	1989-03-17	Traitement de l'acne et des dermatites periorales ainsi que des infections de la peau par le virus de l'herpes

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA000594169A CA1260397B (fr)	1989-03-17	1989-03-17	Traitement de l'acne et des dermatites periorales ainsi que des infections de la peau par le virus de l'herpes

Publications (1)

Publication Number	Publication Date
CA1260397B true CA1260397B (fr)	1989-09-26

Family

ID=4139790

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000594169A Expired CA1260397B (fr)	1989-03-17	1989-03-17	Traitement de l'acne et des dermatites periorales ainsi que des infections de la peau par le virus de l'herpes

Country Status (1)

Country	Link
CA (1)	CA1260397B (fr)

1989
- 1989-03-17 CA CA000594169A patent/CA1260397B/fr not_active Expired

Legal Events

Date	Code	Title
1989-09-26	NARE	Reissued
2002-03-20	MKEC	Expiry (correction)
2002-10-27	MKEX	Expiry

Publication	Publication Date	Title
US4670471A (en)	1987-06-02	Treatment for inflammatory skin disease
US5753270A (en)	1998-05-19	Topical treatment of diseased skin disorders
ES2278393T3 (es)	2007-08-01	Tratamiento antimicrobiano del virus herpes simplex y otras enfermedades infecciosas.
CA1083040A (fr)	1980-08-05	Application locale de medicament par ultasons avec un agent de couplage
CA1222954A (fr)	1987-06-16	Produit pharmaceutique pour le traitement topique de l'acne
EP0305551A2 (fr)	1989-03-08	Compositions pharmaceutiques pour l'application topique
CA2533591C (fr)	2012-11-06	Methode de traitement de plaies et de lesions de la peau
US7655255B2 (en)	2010-02-02	Topical composition for transdermal administration
Püttgen et al.	2021	Neonatal dermatology
US4847283A (en)	1989-07-11	Ointment and method for treating skin lesions due to herpes virus
US5106879A (en)	1992-04-21	Treatment for inflammatory skin disease
US5667790A (en)	1997-09-16	Aluminum chlorhydrate as a treatment for acne and rosacea
CA2671615A1 (fr)	2008-06-12	Composition pharmaceutique topique
EP0078533B1 (fr)	1992-10-21	Composition médicinale pour le traitenant des affections de la peau
CA1260397B (fr)	1989-09-26	Traitement de l'acne et des dermatites periorales ainsi que des infections de la peau par le virus de l'herpes
JPS5877824A (ja)	1983-05-11	インターフェロンを含む組成物
Eriksen et al.	1975	Oral retinoic acid as therapy for congenital ichthyosiform erythroderma
CA1184121A (fr)	1985-03-19	Traitement de l'acne et des dermatites periorales ainsi que des infections de la peau par le virus de l'herpes
US5977176A (en)	1999-11-02	Compositions for the treatment of warts and herpes
CN113081933A (zh)	2021-07-09	祛痘组合物及其制备方法与应用
JPS6327432A (ja)	1988-02-05	高増殖性上皮疾患の治療のための局部的なメトトレキセ−ト調製物およびそれを用いた高増殖性上皮疾患の治療方法
US8492443B2 (en)	2013-07-23	Treatment for herpes simplex virus and other infectious diseases
Nanda	1995	Common dermatoses
Niedelman	1948	Treatment of common skin diseases in infants and children
Emmons et al.	1997	Primary care management of common dermatologic disorders in woman: Pharmacologic considerations